Developer
Seaside Therapeutics, Inc.
Pipeline (1)
- Autism spectrum disorderPhase 2Active
- Fragile X syndromePhase 3Active
- Multiple sclerosisPhase 3Unknown
Deals & partnerships
- ArbaclofenLed by RVL Pharmaceuticals, Inc.
- Aug 21, 2025FinancingAllos Pharma receives a non-dilutive Simons Foundation grant for arbaclofen in autismAllos received a non-dilutive grant from the Simons Foundation to support further clinical development of arbaclofen and biomarker-driven analyses in autism spectrum disorder.
- Aug 21, 2025Licensing dealAllos Pharma acquires global rights to arbaclofenAllos Pharma announced it had secured worldwide rights to arbaclofen, including clinical data, regulatory assets and manufacturing capabilities.
- Sep 18, 2023Licensing dealAllos Pharma obtains worldwide rights to arbaclofen in autism spectrum disorderAllos Pharma announced a new patent family and worldwide exclusive rights to granted patents and clinical programs for arbaclofen in further indications, including autism spectrum disorder.
- Nov 19, 2020Licensing dealAllos Pharma licenses arbaclofen for fragile X syndromeAllos Pharma, founded by Mark Bear and Randall Carpenter (the founders of Seaside Therapeutics), announced exclusive license rights to arbaclofen in fragile X syndrome and said it was preparing the regulatory path to NDA approval.
Catalysts · 2 upcoming · 6 reported
- December 2026Anticipated
ArbaclofenforAutism spectrum disorderRegistry results
ClinicalTrials.gov estimated primary completion of AIMS-2-CT2 (NCT07655115), the arbaclofen shiftability biomarker study in autistic children and adolescents: December 2026.
- January 2028Anticipated
ArbaclofenforMultiple sclerosisRegistry results
ClinicalTrials.gov estimated primary completion of Phase 3 OS440-3006 (NCT05179577), arbaclofen ER 80 mg/day vs placebo in MS spasticity: January 2028. The study is not yet recruiting, with an estimated January 2027 start.
Recently reported
- 2026-01-22missed
ArbaclofenforAutism spectrum disorderFull results
AIMS-2-TRIALS-CT1 (122 ITT, ages 5-17, 16 weeks): no significant effect on the primary Vineland Socialization endpoint or the prespecified key secondary outcomes. All secondary endpoints favoured arbaclofen, with significant improvements on SRS-2, AIM total, some ABC subscales and quality of life. Sleep problems were more frequent on arbaclofen (57.6% vs 34.9%).
- 2023-05-05missed
ArbaclofenforAutism spectrum disorderTopline data
Canadian ARBA trial (POND network) of arbaclofen vs placebo for 16 weeks in autistic children and teens aged 5-17: the Vineland social primary outcome improved but not significantly vs placebo; parent ratings showed gains in some secondary measures.
- 2017-06-12missed
ArbaclofenforFragile X syndromeFull results
Phase 3 209FX301 (adolescents/adults aged 12-50, flexible dose, 125 randomised): no benefit of arbaclofen over placebo on any measure, including the primary ABC-CFX Social Avoidance subscale.
- 2017-06-12missed
ArbaclofenforFragile X syndromeFull results
Phase 3 209FX302 (children aged 5-11, 172 randomised, fixed doses): missed the primary ABC-CFX Social Avoidance endpoint. The 10 mg TID group beat placebo on ABC-CFX Irritability (p=0.03) and the Parenting Stress Index (p=0.03), with trends on Social Avoidance and Hyperactivity.
- 2016-10-17missed
ArbaclofenforAutism spectrum disorderFull results
Seaside Phase 2 of arbaclofen in autism (150 participants aged 5-21): no difference from placebo on the primary ABC Social Withdrawal/Lethargy subscale; a prespecified secondary analysis showed improvement on CGI-Severity.
- 2012-09-19missed
ArbaclofenforFragile X syndromeFull results
Phase 2 crossover of STX209 in 63 FXS subjects: no difference from placebo on the primary ABC-Irritability endpoint; post hoc benefit on ABC Social Avoidance and, in the more socially impaired subgroup, on Vineland-II Socialization.
Recent activity
- Jan 22, 2026ReadoutArbaclofen·Autism spectrum disordermissedAIMS-2-TRIALS-CT1 (122 ITT, ages 5-17, 16 weeks): no significant effect on the primary Vineland Socialization endpoint or the prespecified key secondary outcomes. All secondary endpoints favoured arbaclofen, with significant improvements on SRS-2, AIM total, some ABC subscales and quality of life. Sleep problems were more frequent on arbaclofen (57.6% vs 34.9%).source ↗
- Nov 20, 2025Phase changeArbaclofen·Autism spectrum disorderPhase 2AIMS-2-CT2 (NCT07655115) starts: a single-dose crossover biomarker study followed by 10 weeks of open-label treatment. It is registered as Phase 3 but is not a confirmatory efficacy trial.source ↗
- Sep 18, 2023Phase changeArbaclofen·Autism spectrum disorderPhase 2Allos Pharma announces worldwide exclusive rights to granted patents and clinical programs for arbaclofen in further indications, including autism spectrum disorder.source ↗
- May 5, 2023ReadoutArbaclofen·Autism spectrum disordermissedCanadian ARBA trial (POND network) of arbaclofen vs placebo for 16 weeks in autistic children and teens aged 5-17: the Vineland social primary outcome improved but not significantly vs placebo; parent ratings showed gains in some secondary measures.source ↗
- Mar 20, 2023Phase changeArbaclofen·Multiple sclerosisPhase 3RVL Pharmaceuticals' FY2022 10-K says it is looking to sell or out-license arbaclofen ER tablets. No later disclosure of the program's owner or status was found.source ↗
- Dec 28, 2020Phase changeArbaclofen·Multiple sclerosisPhase 3FDA Complete Response Letter, which recommends a new study to provide substantial evidence of efficacy. The program reverts to a Phase 3 requirement.source ↗
- Nov 19, 2020Phase changeArbaclofen·Fragile X syndromePhase 3Allos Pharma announces exclusive license rights to arbaclofen in fragile X syndrome and says it plans to take it through NDA approval.source ↗
- Jun 1, 2020Phase changeArbaclofen·Multiple sclerosisFiled (NDA)Osmotica resubmits the arbaclofen ER NDA (first submitted in 2015) for spasticity in multiple sclerosis. FDA accepts it as a complete response to its 2016-07-09 action letter and sets a 2020-12-29 goal date.source ↗
- Mar 18, 2019Phase changeArbaclofen·Autism spectrum disorderPhase 2Academic development restarts: the Canadian ARBA trial (NCT03887676, Holland Bloorview / POND network) starts, followed by AIMS-2-TRIALS-CT1 (NCT03682978) on 2019-09-19.source ↗
- Jun 12, 2017ReadoutArbaclofen·Fragile X syndromemissedPhase 3 209FX301 (adolescents/adults aged 12-50, flexible dose, 125 randomised): no benefit of arbaclofen over placebo on any measure, including the primary ABC-CFX Social Avoidance subscale.source ↗
- Jun 12, 2017ReadoutArbaclofen·Fragile X syndromemissedPhase 3 209FX302 (children aged 5-11, 172 randomised, fixed doses): missed the primary ABC-CFX Social Avoidance endpoint. The 10 mg TID group beat placebo on ABC-CFX Irritability (p=0.03) and the Parenting Stress Index (p=0.03), with trends on Social Avoidance and Hyperactivity.source ↗
- Oct 17, 2016ReadoutArbaclofen·Autism spectrum disordermissedSeaside Phase 2 of arbaclofen in autism (150 participants aged 5-21): no difference from placebo on the primary ABC Social Withdrawal/Lethargy subscale; a prespecified secondary analysis showed improvement on CGI-Severity.source ↗
Competitive landscape
Other companies developing against Seaside Therapeutics, Inc.'s targets or indications.
- AB Science1 compoundMultiple sclerosis
- Alkermes plc1 compoundGABA-B receptor
- Definium Therapeutics, Inc.1 compoundAutism spectrum disorder
- F. Hoffmann-La Roche Ltd1 compoundAutism spectrum disorder
- Intra-Cellular Therapies, Inc.1 compoundAutism spectrum disorder
- Neurotech International Limited1 compoundAutism spectrum disorder
- Novartis Pharma AG1 compoundFragile X syndrome
- Principia Biopharma1 compoundMultiple sclerosis
- Tetra Discovery Partners1 compoundFragile X syndrome